S&P 500 comparison · Health Care

Abbott Laboratories vs Becton Dickinson

Prices at close . Model readings .

Abbott Laboratories

$102.64−0.45%
Month: negativeLong run: neutral

Becton Dickinson

$195.16+0.07%
Month: negative
Price change

Price change, with the S&P 500 as a benchmark

Percent change in each close since the start of the chosen range, for both companies and the S&P 500 (SPY). Daily closes over the last year, weekly before that and monthly before five years.

In short

How the two compare

On the latest closes (28 Oct 2026), Abbott Laboratories is the larger company by market value ($179.33B against $53.70B). Over the past year Abbott Laboratories returned −17.8% and Becton Dickinson +35.2%, while the S&P 500 returned +12.7%. The latest filed P/E is 26.1 for Abbott Laboratories and 28.1 for Becton Dickinson, and the operating margin 16.3% against 13.3%. Over the next 21 sessions the model expects −0.15% for Abbott Laboratories, with a 57% chance of a rise, and −0.3% for Becton Dickinson, with a 33% chance. Abbott Laboratories' long-run fair value is $103.76, a gap of +1.1% to its price; the long-run model view is neutral. Becton Dickinson has no published fair value today.

Model view

What the model expects

Expected returns and the chance of a rise from our forecasting models, and the long-run fair value against the price. Readings, not advice.

Model readings:
Expected returnnext 21 sessions
ABT−0.15%
BDX−0.3%
Chance of a risenext 21 sessions
ABT57%
BDX33%
Expected returnnext 63 sessions
ABT+1.69%
BDX+1.26%
Range of outcomes63 sessions, 80% band
ABT−17.3% to +20.7%
BDX−18.6% to +21.1%
Chance of a risenext 63 sessionsMembers only · see plans
Long-run fair valueintrinsic value model
ABT$103.7628 Oct 2026
BDX—The valuation was set at a price in another share basis than this close, so its fair value and gap are not printed.
Gap to pricefair value against the close
ABT+1.1%
BDX—The valuation was set at a price in another share basis than this close, so its fair value and gap are not printed.
Past readings that matchedsign of the 21-session outcome
ABT51.7%of 269
BDX55.8%of 269
Price performance

How the prices moved

Price change over each period, with the S&P 500 (SPY) for comparison.

Closes to
1 monthS&P 500: +1.1%
ABT+1.7%
BDX+7.2%
6 monthsS&P 500: +8.5%
ABT+13.2%
BDX+35.3%
Year to dateS&P 500: +13.3%
ABT−16.6%
BDX+29.6%
1 yearS&P 500: +12.7%
ABT−17.8%
BDX+35.2%
5 yearsS&P 500: +70.7%
ABT−8.6%
BDX+12.1%
1 year against the S&P 500percentage points
ABT−30.5 pts
BDX+22.5 pts
Position in the 52-week range0% low, 100% high
ABT44%close $102.64 in $81.39 to $129.62
BDX93%close $195.16 in $125.21 to $200.47
Against the 200-day average
ABT+1.4%
BDX+18.4%
Valuation

What the market pays

Size and the multiples from the latest filed quarter. A P/E on losses reads n/m.

Filings: quarter to
Market value
ABT$179.33B28 Oct 2026
BDX$53.70B28 Oct 2026
Enterprise valueat the last filing
ABT$159.92B30 Jun 2026
BDX$57.74B30 Jun 2026
P/Elatest filed
ABT26.1
BDX28.1
Price to book
ABT3.00
BDX1.71
EV / EBITDA
ABT17.56
BDX16.25
Free cash flow yield
ABT3.69%
BDX6.56%
Dividend yield
ABT1.95%
BDX1.92%
Questions

Abbott Laboratories or Becton Dickinson: common questions

Which is larger by market value, Abbott Laboratories or Becton Dickinson?

Abbott Laboratories, at $179.33B against $53.70B for Becton Dickinson, on the latest closes (28 Oct 2026).

Which has the higher P/E ratio, Abbott Laboratories or Becton Dickinson?

Becton Dickinson has the higher latest filed P/E, 28.1; Abbott Laboratories' is 26.1. Filings: quarter to 30 Jun 2026.

How did Abbott Laboratories and Becton Dickinson move over the past year against the S&P 500?

Over the past year Abbott Laboratories returned −17.8% and Becton Dickinson +35.2%, while the S&P 500 returned +12.7%. Prices at close 28 Oct 2026.

What does the model expect for Abbott Laboratories and Becton Dickinson over the next month?

−0.15% for Abbott Laboratories with a 57% chance of a rise, and −0.3% for Becton Dickinson with a 33% chance, over the next 21 sessions. Model readings 28 Oct 2026. These are model readings, not advice.

How do the operating margins of Abbott Laboratories and Becton Dickinson compare?

The operating margin is 16.3% for Abbott Laboratories and 13.3% for Becton Dickinson, and the gross margin 56.9% against 46.5%. Filings: quarter to 30 Jun 2026.

Do Abbott Laboratories and Becton Dickinson shares move together?

Over the past year the correlation of their daily returns was 0.48 (loosely together); 1 means they always move together, 0 unrelated, −1 opposite. Prices at close 28 Oct 2026.

In the consoleCompare up to four companies with every model readingMembers see the 63-session chance of a rise and all four horizons, side by side in Research › Compare.
Open in the console
The two company pagesAbbott Laboratories (ABT) forecast and analysisBecton Dickinson (BDX) forecast and analysis
More comparisonsAbbott Laboratories vs Baxter InternationalAbbott Laboratories vs Boston ScientificBecton Dickinson vs GE HealthCareBecton Dickinson vs Idexx Laboratories
BrowseAll Health Care companiesAll comparisonsHow the model readings are made

Model readings are research estimates, not investment advice. Prices: daily closes. Fundamentals: the latest SEC filings. Short interest: FINRA, settlement 30 Sep 2026. A dash means the figure is not in our data; it is never shown as zero. The model view follows a published rule: next month by the sign of the expected return, the long run positive at a fair value 10% or more above the price and negative at 10% or more below it.